Evaluation of oclacitinib maleate and prednisolone combined therapy for the control of atopic dermatitis in dogs: A controlled clinical trial
Veterinary Dermatology · 2025
DOI: 10.1111/vde.13327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Dermatology, 2025. Verfasst von Tássia Sell Ferreira und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Medicine, School of Medicine and Life Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dog Diseases, Prednisolone, Sulfonamides. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Canine atopic dermatitis (cAD) is a chronic inflammatory and pruritic dermatopathy requiring a multimodal therapeutic approach.
Objective
To assess the effectiveness, safety and cost of oclacitinib and prednisolone treatment in dogs with AD. Animals Twenty‐three client‐owned dogs with cAD. Materials and Methods Dogs were randomly assigned to one of two groups: Group 1 received prednisolone (0.5 mg/kg every 24 h) for 7 days, then oclacitinib (0.5 mg/kg) and prednisolone (0.5 mg/kg), were administered alternately with a 1 day pause between each drug, for 7 additional weeks. Group 2 received oclacitinib (0.5 mg/kg every 12 h for 14 days, then every 24 h) for 8 weeks. Assessments included the Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI‐04) and pruritus Visual Analog Scale (PVAS) on Day (D)0, D7, D14, D30, D45 and D60.
Results
Both groups showed significant CADESI and PVAS reductions on D7 ( p < 0.001). From D14 to D60, mean scores remained stable compared to D7, with no significant differences between groups. Adverse events included two dogs with polyuria and polydipsia, and three with polyphagia in Group 1, all of which resolved by D14. In Group 2, one dog experienced polyphagia, and two had self‐limiting vomiting. Three dogs in Group 1 and one dog in Group 2 had mild increases in liver enzyme concentrations. Conclusions and Clinical Relevance The combined protocol was effective and safe for managing itch and inflammation over a 60 day period. It had a 73.3% lower cost compared to oclacitinib alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Medicine, School of Medicine and Life Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil.
- Graduate Program in Rehabilitation Sciences and Physical-Functional Performance, Faculty of Physiotherapy, Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
ORCID-Profile: Tássia Sell Ferreira, Wendy Roldán Villalobos, Vanessa Cunningham Gmyterco, Diogo Simões Fonseca, Marconi Rodrigues de Farias
Zitieren
APA
Ferreira, T. S., Villalobos, W. R., Gmyterco, V. C., Fonseca, D. S., & de Farias, M. R. (2025). Evaluation of oclacitinib maleate and prednisolone combined therapy for the control of atopic dermatitis in dogs: A controlled clinical trial. Veterinary Dermatology. https://doi.org/10.1111/vde.13327
Vancouver
Ferreira TS, Villalobos WR, Gmyterco VC, Fonseca DS, de Farias MR. Evaluation of oclacitinib maleate and prednisolone combined therapy for the control of atopic dermatitis in dogs: A controlled clinical trial. Veterinary Dermatology. 2025. doi:10.1111/vde.13327
BibTeX
@article{Ferreira2025,
author = {Ferreira, Tássia Sell and Villalobos, Wendy Roldán and Gmyterco, Vanessa Cunningham and Fonseca, Diogo Simões and de Farias, Marconi Rodrigues},
title = {Evaluation of oclacitinib maleate and prednisolone combined therapy for the control of atopic dermatitis in dogs: A controlled clinical trial},
journal = {Veterinary Dermatology},
year = {2025},
doi = {10.1111/vde.13327}
}
EUVIMED